CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer
Latest Information Update: 13 Feb 2023
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms CORALLEEN
- 03 Sep 2022 Results assessing health-related quality of life outcomes of pre-operative ribociclib plus letrozole versus chemotherapy from the SOLTI CORALLEEN trial, published in the European Journal of Cancer.
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 Jan 2020 Planned End Date changed from 20 Nov 2019 to 20 Nov 2020.